Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 4Watchful Waiting 2Vincristine 2Filgrastim 2Etoposide 2Cyclophosphamide 2Cisplatin 2veliparib 1omburtamab I-131 1lonafarnib 1imetelstat 1Triiodothyronine 1Radiotherapy, Conformal 1Radiotherapy 1Potassium Iodide 1Platinum 1Observation 1Mesna 1Irinotecan 1Histamine Antagonists 1Granulocyte Colony-Stimulating Factor 1GRN163L peptide 1Dexamethasone 1Chemotherapy, Adjuvant 1Carboplatin 1Bevacizumab 1Antipyretics 1Antiemetics 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ependymoma × veliparib × Clear all
NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡